Hepatitis B Management in Special Populations

  • Author: Alessandra Mangia, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 6/4/18 (What's New)


  • Newer therapies for hepatitis B have increased viral suppression rates and reduced rates of viral resistance following treatment
  • Management of hepatitis B in populations with complex needs may require novel strategies

Although new therapies for hepatitis B introduced in the past 15 years have improved the efficacy of viral suppression and have lowered the risk of antiviral resistance, in certain patient populations, there remain complex issues surrounding hepatitis B prevention and treatment. This module reviews the current data and recommendations for these special populations, with a focus on current clinical practices.

Hepatitis B Virus Coinfection: HIV and Hepatitis C and D Viruses

    Hepatitis B Virus and HIV Coinfection

    • An estimated 5% to 10% of global HBV infections are in HIV-coinfected patients
    • Hepatitis B is generally more aggressive in patients coinfected with HIV, with higher rates of chronicity, higher HBV DNA levels, more frequent reactivation periods, and more rapid progression to cirrhosis[Puoti 2006]
    • HBV causes significant liver-related mortality in HIV-infected patients[...

      Action required